BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

(1) Background: BET bromodomain proteins regulate transcription by binding acetylated histones and attracting key factors for, e.g., transcriptional elongation. BET inhibitors have been developed to block pathogenic processes such as cancer and inflammation. Despite having potent biological activiti...

Full description

Bibliographic Details
Main Authors: Elisa Funck-Brentano, Dzeneta Vizlin-Hodzic, Jonas A. Nilsson, Lisa M. Nilsson
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Epigenetics
Subjects:
bet bromodomain protein
hexamethylene bisacetamide
glioma
Online Access:http://dx.doi.org/10.1080/15592294.2020.1786319

Similar Items

Similar Items